Date: 2017-06-12
Type of information: Nomination
Compound:
Company: Tiziana Life Sciences (UK)
Therapeutic area: Autoimmune diseases - Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 12, 2017, Tiziana Life Sciences announced the appointment of Dr Kunwar Shailubhai (Shailu) as Chief Executive Officer and Chief Scientific Officer with immediate effect. Shailu was previously a Non-Executive Director at the Company. He takes the reins of the company at a significant time for Tiziana Life Sciences, which is developing an orally administered fully human anti-CD3 mAb (foralumab) as a drug candidate to manage NASH, a liver disease for which there is currently no treatment. The timing of his appointment is noteworthy as Tiziana prepares to proceed with Phase II of its trials to develop foralumab as a treatment for NASH.
His appointment follows many years working at Synergy Pharmaceuticals, which he cofounded and where he served as chief scientific officer since 2008.
His pioneering research programme culminated in the development of the drug Trulance™ (plecanatide) which
received FDA approval in January, 2017 for the treatment of adults with chronic idiopathic constipation. Prior to joining Tiziana Life Sciences and Synergy Life Sciences, he worked at Callisto Pharmaceuticals, Monsanto Company and as a senior staff fellow at the National Institutes of Health (NIH).
Financial terms:
Latest news:
Is general: Yes
